| Year |
Citation |
Score |
| 2023 |
Orlow I, Sadeghi KD, Edmiston SN, Kenney JM, Lezcano C, Wilmott JS, Cust AE, Scolyer RA, Mann GJ, Lee TK, Burke H, Jakrot V, Shang P, Ferguson PM, Boyce TW, ... ... Hanniford D, et al. InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. Plos One. 18: e0269324. PMID 37011054 DOI: 10.1371/journal.pone.0269324 |
0.3 |
|
| 2020 |
Hanniford D, Ulloa-Morales A, Karz A, Berzoti-Coelho MG, Moubarak RS, Sánchez-Sendra B, Kloetgen A, Davalos V, Imig J, Wu P, Vasudevaraja V, Argibay D, Lilja K, Tabaglio T, Monteagudo C, et al. Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 37: 55-70.e15. PMID 31935372 DOI: 10.1016/J.Ccell.2019.12.007 |
0.403 |
|
| 2019 |
Floristán A, Morales L, Hanniford D, Martinez C, Castellano-Sanz E, Dolgalev I, Ulloa-Morales A, Vega-Saenz de Miera E, Moran U, Darvishian F, Osman I, Kirchhoff T, Hernando E. Functional analysis of RPS27 mutations and expression in melanoma. Pigment Cell & Melanoma Research. PMID 31663663 DOI: 10.1111/Pcmr.12841 |
0.367 |
|
| 2017 |
Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell & Melanoma Research. PMID 28140520 DOI: 10.1111/Pcmr.12578 |
0.336 |
|
| 2017 |
Simpson D, Ferguson R, Martinez CN, Kazlow E, Moran U, Heguy A, Hanniford D, Hernando E, Osman I, Kirchhoff T. Mutation burden as a potential prognostic marker of melanoma progression and survival. Journal of Clinical Oncology. 35: 9567-9567. DOI: 10.1200/Jco.2017.35.15_Suppl.9567 |
0.319 |
|
| 2016 |
Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. Cancer Medicine. PMID 27169980 DOI: 10.1002/Cam4.667 |
0.33 |
|
| 2015 |
Barbáchano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Carrillo-de Santa Pau E, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Pálmer HG, Rojas JM, Hernando E, Muñoz A. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene. PMID 26455323 DOI: 10.1038/Onc.2015.366 |
0.368 |
|
| 2015 |
Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer. PMID 26308244 DOI: 10.1002/Cncr.29634 |
0.424 |
|
| 2015 |
Hanniford D, Zhong J, Koetz L, Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro RL, Berman RS, Darvishian F, Shao Y, Osman I, Hernando E. A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26089374 DOI: 10.1158/1078-0432.Ccr-14-2566 |
0.467 |
|
| 2015 |
Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E. Abstract 3522: BET and BRAF inhibitors act synergistically against BRAF mutant melanoma Cancer Research. 75: 3522-3522. DOI: 10.1158/1538-7445.Am2015-3522 |
0.323 |
|
| 2014 |
Fleming NH, Silva IEDPD, Miera EVd, Brady BG, Han SW, Hanniford D, Wang J, Shapiro RL, Hernando-Monge E, Zhong J, Osman I. Clinical utility of serum miRNAs for the prediction and early detection of recurrence in melanoma patients. Journal of Clinical Oncology. 32: 9046-9046. DOI: 10.1200/Jco.2014.32.15_Suppl.9046 |
0.441 |
|
| 2013 |
Paoluzzi L, Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Gonzales-Gomez P, Zhang W, Zhang G, Darvishian F, Ohlmeyer M, Osman I, Zhou M, Hernando E. Targeting BET proteins in melanoma: A novel treatment approach. Journal of Clinical Oncology. 31: 9091-9091. DOI: 10.1200/Jco.2013.31.15_Suppl.9091 |
0.338 |
|
| 2013 |
Styrmisdottir EL, Scanlon P, Hanniford D, Eberhardt J, Jones T, Hernando E, Osman I. Melanoma recurrence risk stratification using Bayesian systems biology modeling. Journal of Clinical Oncology. 31: 9089-9089. DOI: 10.1200/Jco.2013.31.15_Suppl.9089 |
0.531 |
|
| 2012 |
Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, Hernando E, Zavadil J, Osman I. Histology-specific microRNA alterations in melanoma. The Journal of Investigative Dermatology. 132: 1860-8. PMID 22551973 DOI: 10.1038/Jid.2011.451 |
0.423 |
|
| 2012 |
Ma MW, Farhadian JA, Friedman EB, Miera EVd, Hanniford D, Segura MF, Berman RS, Shapiro RL, Pavlick AC, Zavadil J, Hernando E, Osman I. MicroRNA alterations associated with BRAF status in melanoma. Journal of Clinical Oncology. 30: 8565-8565. DOI: 10.1200/Jco.2012.30.15_Suppl.8565 |
0.505 |
|
| 2012 |
Hernando E, Hanniford D, Shang S, Segura MF, Pavlick AC, Berman RS, Shapiro RL, Darvishian F, Osman I, Shao Y. Early alterations of microRNA expression to predict and modulate melanoma metastasis. Journal of Clinical Oncology. 30: 8550-8550. DOI: 10.1200/Jco.2012.30.15_Suppl.8550 |
0.433 |
|
| 2011 |
Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 20: 104-18. PMID 21741600 DOI: 10.1016/J.Ccr.2011.05.027 |
0.378 |
|
| 2011 |
Rose AE, Wang G, Hanniford D, Monni S, Tu T, Shapiro RL, Berman RS, Pavlick AC, Pagano M, Darvishian F, Mazumdar M, Hernando E, Osman I. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell & Melanoma Research. 24: 197-206. PMID 20883453 DOI: 10.1111/J.1755-148X.2010.00784.X |
0.353 |
|
| 2010 |
Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E. Melanoma MicroRNA signature predicts post-recurrence survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1577-86. PMID 20179230 DOI: 10.1158/1078-0432.Ccr-09-2721 |
0.583 |
|
| 2009 |
Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences of the United States of America. 106: 1814-9. PMID 19188590 DOI: 10.1073/Pnas.0808263106 |
0.443 |
|
| Show low-probability matches. |